Outcome of Board Meeting dt 28-05-2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of 3B BlackBio Dx Ltd approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone revenue from operations grew ~28% YoY to Rs. 9052.97 lakhs, while profit after tax jumped ~39% to Rs. 4755.95 lakhs; consolidated revenue rose ~30% to Rs. 9646.86 lakhs with PAT up ~48% to Rs. 4759.11 lakhs. EPS stood at Rs. 55.51 (standalone) and Rs. 55.66 (consolidated). The Board recommended a final dividend of Rs. 4.00 per share (40%) for FY25, subject to shareholder approval. Statutory auditor Baheti & Co. issued an unqualified opinion. Additionally, Mr. Praveen Kumar Rai was appointed as Secretarial Auditor for FY 2025-26 to FY 2029-30, and M/s Ali Jain & Sharma as Internal Auditor for FY 2025-26.
Strong double-digit growth in both revenue and profits signals healthy business momentum, mainly driven by the diagnostic kits segment. The proposed final dividend of Rs. 4/share reflects good cash generation and is positive for shareholders, while the unqualified auditor report adds credibility.